Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Average Rating of “Buy” from Analysts

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) has been assigned an average rating of “Buy” from the eight ratings firms that are presently covering the company, MarketBeat Ratings reports. Eight equities research analysts have rated the stock with a buy recommendation. The average 1-year price target among brokerages that have covered the stock in the last year is $6.63.

Several equities research analysts recently issued reports on TSHA shares. Chardan Capital reissued a “buy” rating and issued a $7.00 target price on shares of Taysha Gene Therapies in a research report on Wednesday, February 26th. Needham & Company LLC reiterated a “buy” rating and issued a $6.00 price target on shares of Taysha Gene Therapies in a report on Thursday, February 27th.

Hedge Funds Weigh In On Taysha Gene Therapies

Several hedge funds and other institutional investors have recently made changes to their positions in TSHA. Ground Swell Capital LLC acquired a new stake in Taysha Gene Therapies in the 4th quarter valued at $25,000. Creative Planning acquired a new stake in shares of Taysha Gene Therapies in the third quarter valued at about $28,000. Cibc World Markets Corp purchased a new stake in shares of Taysha Gene Therapies during the 4th quarter valued at about $28,000. E Fund Management Co. Ltd. acquired a new position in Taysha Gene Therapies during the 4th quarter worth approximately $31,000. Finally, Hsbc Holdings PLC boosted its holdings in Taysha Gene Therapies by 65.6% in the 4th quarter. Hsbc Holdings PLC now owns 20,391 shares of the company’s stock worth $36,000 after acquiring an additional 8,076 shares during the period. Institutional investors and hedge funds own 77.70% of the company’s stock.

Taysha Gene Therapies Price Performance

TSHA stock opened at $1.79 on Tuesday. The stock has a market capitalization of $366.95 million, a price-to-earnings ratio of 2.84 and a beta of 0.91. The company has a quick ratio of 5.51, a current ratio of 5.51 and a debt-to-equity ratio of 0.48. Taysha Gene Therapies has a 52-week low of $1.19 and a 52-week high of $4.32. The stock’s fifty day simple moving average is $1.65 and its 200-day simple moving average is $1.94.

Taysha Gene Therapies (NASDAQ:TSHA) last released its earnings results on Wednesday, February 26th. The company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.08) by $0.01. The firm had revenue of $2.02 million for the quarter, compared to the consensus estimate of $2.05 million. Taysha Gene Therapies had a negative return on equity of 106.36% and a negative net margin of 229.67%. Equities research analysts expect that Taysha Gene Therapies will post -0.35 EPS for the current year.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.